Palisade Bio shares are trading higher after FDA approval of its Investigational New Drug application for PALI-2108, which allows the compan
Palisade Bio shares are trading higher after FDA approval of its Investigational New Drug application for PALI-2108, which allows the company to start its Phase 2 ASCENTRA-UC trial in patients with ulcerative colitis.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.